Dow Tumbles Over 100 Points; US Jobless Claims Fall to 197,000
U.S. stocks fell Thursday as tech slid; jobless claims beat estimates. Oil rose, while APUS surged 245% and BENF plunged 33%.
Stocks · News reference
Artelo Biosciences Files Provisional Patent Application For ART27.13 As Monotherapy And In Combination With GLP-1 Receptor Agonists
As reported, ART27.13 produced approximately 40% weight loss in combination with semaglutide and approximately 20% as monotherapy, comparable to semaglutide, in obese mice over four weeksApplication expands Artelo’s
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Why GlucoTrack Shares Are Trading Higher By Around 118%; Here Are 20 Stocks Moving Premarket
GlucoTrack surged 117.7% premarket after Lokahi Therapeutics signed its first external partnership; other stocks saw notable gains and losses.
Artelo Biosciences (ARTL) Stock Surges Wednesday: What's Happening?
Artelo Biosciences, Inc. (NASDAQ: ARTL) shares are surging Wednesday afternoon after the clinical-stage biopharmaceutical company announced the filing of a new provisional patent application covering its drug candidate ART27.13 for the treatment of obesity.
Artelo Biosciences shares are trading higher after the company announced the filing of a provisional patent application for ART27.13 as a monotherapy and in combination with GLP-1 receptor agonists.